Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Titel:
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Auteur:
Reich, Kristian Papp, Kim A Blauvelt, Andrew Tyring, Stephen K Sinclair, Rodney Thaçi, Diamant Nograles, Kristine Mehta, Anish Cichanowitz, Nicole Li, Qing Liu, Kenneth La Rosa, Carmen Green, Stuart Kimball, Alexa B